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Abstract
Metastasis is the primary cause of mortality in cancer patients. Inhibition of proteins that
are involved in the regulation of metastasis are expected to suppress metastasis and
represent treatment targets. Our focus is on prostate cancer metastasis and we have
developed a novel high-throughput means of performing in vitro screens for regulators of
prostate cancer metastasis. We propose to use a focused CRISPR library screen that will
“knock out” all human kinases to determine which ones are responsible for prostate cancer
metastasis. CRISPR is a potent genetic editing tool and was used to silence all kinases in
prostate cells (BPH cells). These cells form spheroid colonies in 3D culture and were
subjected to a CRISPR kinase screen. We observed a morphological change in some
colonies to a stellate morphology, which represents aggressive behavior. These stellate
colonies were then isolated to identify the responsible kinase. We identified Glycogen
synthase kinase 3 beta (GSK3ß) as a potential regulator for prostate cancer cell morphology
and possible, metastasis.
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Chapter 1

1 Introduction
1.1 Cancer
Cancer is a group of diseases that involve abnormal cell behaviour, such as uncontrolled
cell proliferation and resistance to apoptosis. Tumors regularly evolve from a single
transformed cell with few mutations. Clonal evolution of the initiator cell will acquire
additional characteristics under the selective stresses of an environment, such as
invasiveness and aggressiveness [1]. Malignant cells within a tumor can vary in terms of
the quality and quantity of mutations leading to a biologically important property known as
tumor heterogeneity. This heterogeneity underlies the difficulty in identifying and
neutralizing therapeutic/molecular targets [2].
Cancer and the severity of side effects and complications caused by its treatment
significantly shorten a patient’s lifespan. In addition, cancer and its management pose a
significant economic burden. In the United States, neoplastic diseases cost $124 billion in
2010, and are projected to increase to $157 billion in 2020 [3]. A number of risk factors are
associated with the development of various cancers. These include age, ethnicity, diet,
immune system, and family history [4]. Interestingly, Asian populations are less susceptible
to certain types of cancer than other ethnicities; however, in the second generation of Asian
immigrants who lived in western societies, the susceptibility to developing cancer
increased. This observation suggested environmental factors and a diet switch from
vegetables and seafood to red meat and beer as potentially being involved [5].
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1.2 Prostate Cancer
Prostate cancer (PCa) is the most diagnosed disease in the developed world. It is more
likely to affect elderly people compared to other age groups [6]. One in seven Canadian
men will develop PCa throughout his lifespan. In 2016, approximately 21,600 Canadian
men were diagnosed with PCa and almost 4000 died from it. There are multiple factors that
contribute to PCa formation, such as nutrition factors, habit-related factors, androgens, and
ethnicity [6]. The Multiethnic Cohort Study (MCS) for statistics revealed that PCa is largely
diagnosed in men of African descent compared to their ethnic counterparts in the United
States [7], [8]. Patients with prostate cancer are treated with hormone therapy called
androgen deprivation therapy (ADT). ADT inhibits androgen production from its main
source or blocks its cellular receptor-mediating signaling cascade [6]. In addition, blocking
critical pathways for PCa such as Hedgehog, fibroblast growth factor (FGF), transforming
growth factor beta (TGF-β), Src, and integrins has been used for PCa patients [9]. Some
patients cease to respond to this therapy and develop resistance. This resistance allows PCa
to progress in an androgen-independent manner. The second line of treatment is
chemotherapy, which is typically docetaxel and cabazitaxel. These treatments stabilize
microtubules of rapidly dividing cells [10] and can extend the survival rate by 2-4 months
[11], [12]. Other drugs can be used as a second line treatment are based on the individual
patient characteristics such as sipuleucel-T (immunotherapy) and radium-233 dichloride
(223R) (radiotherapy) [13], [14]. Resistance to ADT is also associated with migration of PCa
to distant sites such as the bone, brain, liver, and lymph nodes, by a process called
metastasis.
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1.3 Cancer Metastasis
Cancer metastasis is the leading cause of cancer related-death [15]. Metastasis consists of
four key steps: 1) intravasation, when a cancer cell detaches from the primary tumor and
enters into the blood circulation, 2) extravasation, when cancer cells exit the blood
circulation; 3) micrometastases formation in the new environment, and 4) colonization,
when these micrometastases progress into a macroscopic tumor [4], [16]. To initiate this
cascade, the cancer cells must first acquire invasive characteristics [17]. One key process
in acquiring an invasion capacity is the degradation of the surrounding extracellular matrix
and cell protrusion formation [15]. This morphological change is followed by a phenotypic
switch in cancer cells from an epithelial to mesenchymal transition (EMT). This mechanism
converts the epithelial cells from its polar state into to migrating, fibroblast-like
mesenchymal cells. Under physiological conditions, EMT phenomenon is a reversible
process as shown during embryogenesis [18].
Cancer metastasis, overall, is an inefficient process. Very few cancer cells eventually are
able to establish new metastatic colonies [19]. Therefore, metastatic cells which have
intravasated into the blood circulation may not successfully go through the extravasation
step, which leads to failure in extravasated cell colony formation. In addition, a significant
number of extravasated cells are believed to undergo programmed death within 24 hours
[20]. The surviving extravasated cells are also not guaranteed to proliferate into a cancer
colony and may remain in the dormant state [21], [22], [23]. Therefore, successful
metastatic growth requires cancer cells to overcome a number of obstacles, such as the
immune system, blood forces, a harsh environment, hypoxia, and acidity [10]. Metastatic
cancer cells evade host immunity via several mechanisms. It has been reported that
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metastatic cells disguise themselves from natural killer cells (NK) by expressing
coagulation factors VIIa and X [24], [25]. Interestingly, treatment with anticoagulants has
been shown to attenuate metastatic burden in animal models and in cancer patients [26].
The microenvironment at the secondary site also regulates the metastatic process. The “seed
and soil” hypothesis was first put forward by Stephen Paget in 1889 and suggested that
metastasis is not a completely random process [27]. This theory suggests that cancer cells
from an individual tumor tend to home to a specific secondary site. For example, metastatic
melanoma skin cancer predominately homes to liver [28], [29], and other metastatic cancer
such as lung, breast, and prostate mainly metastasize to bone [30]. A recent study confirmed
the seed-soil hypothesis by implanting tumors in uncommon metastatic sites, wherein the
environment was hostile for said tumor; however, tumors were “rescued” when implanted
in a favorable metastatic site [31]. Several lines of evidence have discovered that the role
of microenvironment at the secondary site manipulates the fate of the metastatic cell by
recruiting bone marrow-derived cells [32]. For example, hypoxic conditions in the primary
site may favor premetastatic niche formation as a result of three events: 1) production of
lysyl oxidase (LOX) that will alter the tumour's microenvironment; 2) production of
chronic anhydrase (CAIX) that will mobilize myeloid-derived suppressor cells (MDSCs);
and 3) suppression of natural killer (NK) cell activation. Metastatic cells exhibit predetermined directional behaviour [20].
In terms of bone metastasis, the marrow has a high number of blood vessels and an
abundance of growth factors, and an hypoxic environment (1-7% O2), providing the cancer
cells a fertile environment [4]. In addition, osteoblasts highly express adhesive molecules
which interact with corresponding receptors on cancer cells [33]. It is not surprising that
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bone is a common metastatic site for a number of human cancers as this tissue is one of the
the first tissues to encounter circulating tumor cells (CTC) [34]. The mutually beneficial
relationship between osteoblasts and cancer cells is supported by secretion of growthpromoting factors such as insulin-like growth factors (IGF)-1 and –2, TGF- ß, prostatespecific antigen (PSA), urokinase-type plasminogen activator (uPA), fibroblast growth
factors (FGF)-1 and -2, bone morphogenetic proteins (BMPs), platelet-derived growth
factor (PDGF) and endothelin-1 (ET-1) [35].
The majority of patients (approximately 90%) with metastatic PCa develop metastases in
the bone and the rest develop metastases mainly in the brain and lymph nodes. Mortality
for prostate cancer metastasis is the highest compared to other bone metastasis associated
cancers [11]. Patients with metastatic PCa in the bone exhibit sclerotic bone lesions
associated with an increase in osteoblasts [13]. These symptoms can be mitigated at this
stage by radiotherapy or osteocyte inhibitors [14]. However, cancer becomes hard to treat
when it has metastasized to the bone by affecting bone remodeling processes and leaving
patients with severe pain, pathological fractures, hypercalcemia, and spinal and nerve
compression [36], [37].

1.4 CRISPR-Cas9 System
A genomic editing tool is a potent approach to delineate which genes or pathways are
involved in cellular processes, which can be potentially targeted therapeutically [38]. This
emerging approach has been effectively used in different organisms for multiple purposes.
Genomic editing tools, in particular the CRISPR-Cas9 system, has been harnessed for
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multiple biomedical assay generation, phage-resistant dairy cultures, and phylogenetic
classification of bacterial strains [39].

1.4.1 Gene Modification
There are two types of gene dysregulations which can be utilized. The first one is knocking
down a gene product. Knockdowns work at the RNA level and generate gene
downregulation by using single short hairpins (shRNAs) or interference (siRNA).
However, this approach may be unable to provide a genuine phenotypical effect due to
targeting the gene of interest [40] as it is only limited to transcribed elements and the effect
may be short-lived [41]. The second method is knocking out a gene. Knockouts work at the
DNA level to generate a complete loss of gene function. There are multiple techniques for
knocking genes out, including meganucleases, Zinc-finger nucleases, transcription
activator-like effector nuclease (TALEN), and regularly clustered interspaced short
palindromic repeats (CRISPR). These programmable nucleases are subdivided into two
groups based on the type of interaction which takes place with the DNA: 1) zinc finger and
transcription activator-like effector nucleases (ZFN and TALEN, respectively) which target
DNA via a protein; 2) the CRISPR-Cas system, which targets DNA by short guide RNA
that base-pairs with DNA.
The CRISPR-Cas system is a unique gene editing tool. It is relatively simple to use and
does not require a need to design a cleavage enzyme because of the power of the CRISPRassociated protein (Cas9). Cas9 has also been shown to slice methylated DNA [44].
CRISPR-Cas9 consists of two elements: an oligonucleotide RNA [42] for directing and
Cas9 protein which introduces double-strand breaks (DSBs) [43]. The DNA break is then
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repaired through nonhomologous end-joining (NHEJ) or homology-directed repair (HDR).
NHEJ causes insertions and deletions (indels), and frame shift mutations resulting in a gene
knockout. HDR pathway is useful for knocking in genes (inserting) in the presence of a
repair template [44], [45]. A range of vectors can be used for introducing genetic material
into cells in viral or non-viral formats. For viral vectors, adenoviruses, adeno-associated
viruses, and lentiviruses are typically used. An advantage of the lentiviral format is that it
is non-replicative, safe, and can incorporate long DNA material (ideal for the CRSIPRCas9 system) [46]. Lentiviral vectors do present safety concerns but scientists have
developed newer generation formats to overcome these concerns. Importantly, these new
generation format separates the packaging, transfer, and envelop into separate vectors.

1.4.2 CRISPR as a Natural Phenomenon
Microbiologists interested in studying the defense mechanisms of microorganisms against
invaders discovered the CRISPR-(Cas)9 system. This system functions as an immune
system in bacteria and archaea to fend off viruses, phages, and plasmids. This microimmune system shares similarities with the mammalian immune system with respect to
precision, diversification, and recognition [50]. In contrast to the non-inheritable eukaryotic
expression system, the bacterial CRISPR-Cas9 is an inheritable adaptive system [47].
A CRISPR locus is defined as an array of short direct repeats interspersed with spacer
sequences. The spacer content of these CRISPR arrays reflects the different phages and
plasmids that the host has encountered. Bolotin and his group sequenced the spacers and
found a substantial match with the genome of phages and other invaders. They also showed
that the high number of spacers is associated with the immune system potency [48]. When
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the host encounters an invader, the DNA of invading microorganism is cleaved by the Cas
proteins and the sequence is recorded. The sequence is then transcribed, forming small
RNA called CRISPR RNA (crRNA). When the host encounters the invader again, the
crRNA binds the sequence of invading DNA leading to cleavage [18, 27] (Fig 1). Cas
proteins are unable to start cleaving unless the DNA region of interest is followed by a
Protospacer Adjacent Motif (PAM). Jink et al. tested the role of PAM by conducting a
cleavage assay using wildtype and mutant PAM. They showed that DNA was not cleaved
with the mutant PAM but was readily cleaved with the wildtype PAM. This observation is
important and supports why protospacers are not cleaved as the PAM sequence is not
present at the CRISPR locus of the bacteria [38]. Also, Cas9 preferentially binds sgRNAs
containing purines in the last four nucleotides of the spacer sequence, whereas pyrimidines
are not favored [41].

1.4.3 CRISPR-Cas9 System Types
Bacteria have a few different CRISPR systems. The Cas structure and its mode of function
can be used to broadly divide CRISPR into three different types. Type Ι is found in
Escherichia coli and type ΙΙΙ is found in Staphylococcus epidermidis and Pyrococcus
furiosus. These two types have multiple Cas proteins that generate genetic modifications.
CRISPR type ΙΙ is the preferred type to be used as a tool and has Cas9 as the only member
of that family to meditate cleavage [38]. CRISPR type II system is found in the
Streptococcus thermophilus.
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Cas9 protein consists of two domains: a HNH domain for cleaving complementary strands
and a RuvC domain for cleaving the noncomplementary strands [18]. It has been shown
that mutating one of these domains inhibits Cas9 from generating a complete cleavage. A
number of engineering advancements have been made in the CRSIPR-Cas9 system. Offtarget effects in this system have been tested by designing multiple variants of sgRNA with
one to four mismatches of complementary DNA. Mismatches near the 5` end tend to be
more tolerated than near the 3` end [49]. In 2016, Slaymaker and colleagues drastically
potentiated Cas9 by manipulating the charges of both Cas9 domains and reduced off-targets
[50]. Based on the native Cas9 crystal structure, it was found that the crystal structure of
modified Cas9 is highly positively charged, which helped it to facilitate the unwinding of
the negatively charged DNA. Thus, lowering the positive charge of Cas9 increases the
specificity of sgRNA.

1.4.4 CRISPR Screen In vitro
Genomic screening is of critical importance for identifying the roles of the genes involved
in cellular processes associated with pathological disorders. Typically, genomic screens are
performed by inducing mutations resulting in either a gain of function (GOF) or a loss of
function (LOF). Standard GOF utilizes overexpression of cDNA. The size of cDNA is
relatively large compared to the vector making the process difficult. LOF, on the other
hand, typically utilizes RNA templates [51]. Genomic screens of CRISPR-Cas9 can
provide a positive or negative selection environment. A positive screen allows for the
discovery of genes being mutated by sgRNAs which enhance cell proliferation (for
example, tumor suppressors). Chen and his colleagues performed a CRISPR screen for the
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entire genome by knocking out genes in non-small cell lung cancer (NSCLC). They
identified genes responsible for tumor suppression when mutated. These genes included
well-known tumor suppressors such as neurofibomin (NF1) and phosphatase and tensin
homolog (PTEN) [52]. In contrast to positive screens, negative screens select for genes that
are responsible for cell survival (identifying oncogenes) [53].

Figure 1: CRISPR-Cas system naturally requires three phases to take place.
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This figure was published in R. Barrangou and L. A. Marraffini, “CRISPR-cas systems:
Prokaryotes upgrade to adaptive immunity,” Mol. Cell, vol. 54, no. 2, pp. 234–244, 2014.
The figure is being reproduced for educational purposes only and not for any commercial
use. Figure is included in the M. Sc. dissertation with attribution.

1.5 Kinases
Cells are surrounded and triggered by external stimuli. In response to these stimuli, cells
initiate a cascade of intracellular signalling pathways. One of the important mediators for
these complicated pathways are kinases, which shuttle the γ-phosphate group from the
adenosine triphosphate (ATP) to other molecules with a phenolic group of the tyrosine, or
an alcoholic group of the serine, and threonine residue [54], [55]. This process, called
phosphorylation, is counter to the process carried out by phosphatases. Phosphorylation is
recognized as the predominant post-translational modification compared to methylation,
glycosylation, and acetylation, etc. [56]. According to the human genome sequencing
project, there are 518 kinases in every 2000 gene-encoded enzymes [57]. When a protein
gets phosphorylated, it may start functioning in critical biological processes such as
proliferation, migration, differentiation [58], and cytoskeleton arrangement [59]. It is
assumed that one-third of cellular proteins are phosphorylatable [56]. The kinase family
commonly comprise a catalytic domain of 250-300 amino acids. Tyrosine kinases are
divided into two groups based on cellular location; those that exist on the cellular membrane
are called receptor tyrosine kinases (RTKs), and cytosolic kinases are called non-receptor
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tyrosine kinases (NRTK). All RTKs are monomers with an exception of the insulin receptor
[60].

1.5.1 Kinase Involvement in Cancer
Because of the involved on kinases in various cellular processes, it is likely that aberrant
expression of kinases will cause a disease or be associated with disease progression. Kinase
deregulation has been linked to approximately 400 pathological disorders including cancer
[61]. The vast majority of the oncogenes are recognized as kinases. Thus, any dysregulation
in kinases is desirable for establishing cancer [62]. It has been reported that most human
cancers exhibit an anomalous expression of kinases. For example, kinases have been shown
to function aberrantly in breast, lung, prostate, and colorectal cancer [63]–[65]. In the
Cancer Gene Census, it was revealed that 10.7% of cancer genes have kinase domains [66].
It is generally assumed that kinases are tumor initiators and phosphatases act as tumor
suppressors. However, several lines of evidence reveal that kinases can also function as
tumor suppressors [59], [67]. A recent study identified a kinase called Raf kinase inhibitor
protein (RKIP), which acts as a metastatic suppressor gene, but behaves differently in
prostate cancer. Downregulation of this protein leads to angiogenesis and acquisition of
invasive characteristics in cancer cells, as well as resistance to chemotherapy-induced
apoptosis [68]. Therefore, aberrant expression of or dysfunction in kinases is a cancer driver
whether by conferring oncogenic capacity or tumor suppression capacity.
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1.5.2 Kinases as Therapeutic Targets
Chemotherapeutic agents are still the first line of treatment for cancer patients. However,
the problem associated with this treatment is its failure to discriminate normal cells from
malignant cells, leaving patients with harsh side effects such as the loss of hair/nail and
taste sensation. Thus, there is an urgent need to develop drugs with high specificity and
minimal side effects. An avenue is targeting cancer cell-associated signaling pathway [69].
As mentioned above, one of the critical mechanisms in signaling transduction is protein
phosphorylation [70]. Tyrosine Kinase Inhibitors (TKIs) succeed in diminishing
phosphorylation and resulting in suppressing the tumor with minimal cytotoxicity
compared to chemotherapy. These inhibitors greatly inhibit some of the hallmarks of cancer
such as angiogenesis by vascular endothelial growth factor (VEGFR) inhibition, cell
differentiation by mitogen-activated protein kinase (MAPK), and cell proliferation by
cyclin-dependent kinase (CDK) [71]. An example of a TKI with high specificity and low
side effects is Imatinib which has been used for chronic myeloid leukemia [CML] patients
[72], [73]. Kinase activity suppression can be achieved by several ways: blocking the ATP
pocket, interrupting protein-protein interactions, and genetic modulations [61]. The next
generation of anticancer drugs has focused largely on targeting main cancerous pathways
such as TKs by administering consecutive or combined drugs and doses [32]. Within just
three years, the pharmaceutical industry has witnessed an astonishing outpouring of drug
discovery by approving 15 TK inhibitors between 2012-2015 [74]. The existence of 100200 protein kinases per cell that reside upstream and downstream of tumor drivers with
druggable potential has led investigators to heavily study them [75]. Kinases are considered
the second most popular therapeutic target after G protein-coupled receptors (GPCRs) [76].
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One advantage of TKs over GPCRs is that an antagonist for a TK leads to the suppression
of more than one cellular response, while GPCRs suppression leads only to suppression of
one cellular response. This might increase the potency of TK, since the hallmarks of cancer
cannot be suppressed by inhibitors that antagonize a single cellular response [4]. Kinase
pathways play an essential role in tumorigenesis and inhibiting one may be compensated
by another pathway [32]. Suppressing multiple pathways simultaneously might be useful
for efficient destruction of the cancer cells. It can, however, be problematic as a result of
drug metabolism. For example, the metabolism of one of the two inhibitors can interfere
with the other one. Thus, a single multi-kinase inhibitor may potentially be robust and safe
[78].
Kinase activity can be suppressed by two approaches: 1) a monoclonal antibody such as
trastuzumab and cetuximab, or 2) a small-molecular inhibitor such as Imatinib or Sunitinib.
The former approach is commonly used for receptor tyrosine kinase (RTK) inhibition, and
these agents are typically administered intravenously due to their large size (150 kDa).
Small molecule inhibitors (approximately 500 Da) are used for non-receptor tyrosine
kinases (NRTK) and are administered orally [85]. KIs are less specific compared to
monoclonal antibodies (mAbs) as KIs may suppress several signalling pathways. mAbs can
activate immune responses such as antibody-dependent cell-mediated cytotoxicity (ADCC)
and complement-dependent cytotoxicity (CDC). Antibody-mediated therapy has been
shown to be more effective compared to KIs in vivo compared to in vitro settings. For
example, gefitinib was more effective than cetixiumab in killing small-cell lung cancer
(NSCLC) in vivo; however, these different drugs showed the opposite in the in vitro model,
possibly due to mAB-induced immune responses.
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1.6 Screening Approach
Different screening methods can be applied to the whole genome or select libraries using
gene deletion or gene silencing strategies. Downstream analyses of these screens vary based
on the nature of study. In order for cells expressing sgRNA/RNAi/shRNA to be considered
a ‘hit’, the cells must exhibit a phenotypic change which can be tumor formation, apoptosis,
dormancy, or differentiation [77]. For example, cells introduced to RNA-mediated
mutations were selected with a BRAF inhibitor (vemurafenib) and the surviving clones
revealed genes whose loss conferred resistance to this drug [78]. Another study also used a
similar approach with an Akt inhibitor to reveal genes conferring vulnerability to this
inhibitor [79]. The kinase family is the most widely screened library aside from the whole
genome. A recent screen for kinases was performed to identify genes that are required for
the proliferation of cells that overexpress the KRAS gene. Several hits were identified, such
as PLK1, STK33, and TBK1 [80]–[82]. There have been several attempts to screen for
kinases that are indispensable for cancer cell propagation and survival [83]. A genomewide screen for different pathological arrays was conducted in different model systems,
e.g., yeast [84], worms[85], Drosophila [86], mouse cells [52], [87], and human cells[88],
[89]. Wang and colleagues conducted a whole-genome screen to identify genes essential
for cellular proliferation, selecting genes whose mutation exerted a selective disadvantage
for the cells.

16

1.7 Models for Studying Cancer Metastasis
There are multiple approaches to study cancer metastasis, whether in vitro or in vivo.
Angiogenesis, cell migration, and cell invasion are of particular importance for metastatic
dissemination, and these features can be recapitulated in vitro through the tube formation,
scratch wound, gelatin degradation, and Boyden chamber assays [90]. On the other hand,
for an in vivo study, mouse models of different cancer types are widely used [91]. There
are multiple ways of establishing cancer in mice, including administering the cancer into
immunocompromised mice, spontaneous formation by a genetically engineered mouse
(GEM), subcutaneous injection to establish a primary tumor, and tail vein injection for
monitoring extravasation and colonization. These mice are typically further treated to
evaluate efficacy of chemotherapeutic drugs or small-molecule inhibitors. GEM models
allow precise molecular specificity to study the effects of the gene of interest on cancer and
its resistance mechanisms to different therapies [92]. Tumors developed in the GEM model
can be dissected and transplanted into immunocompetent mice to assess immunotherapy
[93]. Another mouse model is the severe combined immune deficiency (SCID) mouse,
which is used to study the tolerance of foreign tissue transplants (xenografts). Furthermore,
it is well known that it takes a long time to acquire results from cancer mouse models;
therefore, we utilize the chorioallantoic membrane (CAM) model.

1.8 Chorioallantoic Membrane (CAM)
Animal models are the gold-standard for preclinical studies, especially for cancer research
[94]. However, animal models are expensive and time-consuming with respect to
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regulatory guidelines as well as disease recapitulation. Moreover, with the exception of the
genetic murine model, there is a lack of a model which mimics all metastatic cascades,
including extravasation, intravasation, and colonization [95]. The avian model is an
excellent option to circumvent some of these difficulties. The CAM of the chick embryo is
a very thin organ composed of three layers: ectoderm, mesoderm, and endoderm [96]. The
CAM functions as a respiratory system for the chick embryo since it is aligned through the
porous eggshell. It enables the embryo to exchange gases through these pores, and helps
transport electrolytes from allantoic sacs and calcium from the shell.
This model is naturally immunodeficient in early stages, cost-effective, amenable to realtime intravital imaging, and highly vascularized with good lymphatic drainage [94], [97].
With the advancement of imaging technology, the CAM model allows tracking injected
dyes and cells to illuminate the capillary network, and both extravasated and intravasated
cells [19]. As mentioned earlier, the main mediator of cancer cell metastasis is the blood
canal [16]. Two out of three key steps of the metastatic cascade take place in the blood
vessels. Therefore, the CAM model can be used as a window for monitoring the cancer
metastasis cascade. For example, we can assess micrometastases formation, extravasation
efficiency, cancer cell survival, and dormancy. In addition, intravasation efficiency can be
performed via bolus injection, which takes place by injecting cells in the stroma of the
CAM [96]. On-planting a Patient Derived Xenograft (PDX) on top of the CAM after
slightly tearing it allows for assessment of angiogenesis..
There are limitations associated with this CAM model. Timing of this experiment is
relatively short, which means macrometastases cannot be observed [98]. The survival rate
for chicks after the experiment is low at 65-70% even under ideal experimental conditions.
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Dynamic angiogenesic responses are also difficult to observe [99]. Lastly, shell traces left
following cracking of the eggs may induce inflammation and angiogenesis [99].
In my studies, we performed an intravenous injection of cells to assess tumor colony
formation. In these studies, cells intravasate the blood vessels at day 9. It has been shown
that there is a substantial increase in endothelial cell number at this age [94] (Fig 2).

19

Figure 2: Chorioallantoic Membrane (CAM) of the Chick Embryo Model after
Cracking.
Fertilized eggs cracked three days after incubation were placed in a blue container. At day
9, an expansion of blood vessels seems to appear for performing an IV injection and other
assays.
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1.9 Cell morphology as a readout of metastasis and invasive
behavior
The change in cell shape is of critical importance for metastatic cancer cells and allows
movement of cells from one site to another. Metastatic cells have the capacity to adapt to
each new site by manipulating cell shape in order to proceed with the metastatic steps. One
study did a pairwise comparison between two set of cells with different metastatic
potentials (high and low). They found significant differences between the two sets in terms
of cell volume and elongation. In vitro studies such as three-dimensional (3D) culture
assays which allow individual cells to expand clonally and form colonies. Colonies from
metastatic cell lines exhibit two morphologies, round and stellate. Stellate morphology is
considered to be illustrative of aggressiveness. For example, in some triple negative breast
cancers (TNBC), which is a highly aggressive stage in breast cancer, cell lines formed a
stellate morphology in 3D Matrigel cultures [100]. In addition, when they were treated with
enzalutamide, an androgen receptor (AR) antagonist, there was a significant shift into round
morphology. They also conducted several assays in order to assess critical steps in
metastasis and found that AR inhibition reduced migration and invasion. Thus, migration
and invasion results were aligned with the phenotypic shift in 3D cultures after treatment.
Another group conducted a study with a panel of 25 cell lines using 3D cultures in order to
observe colony morphology [101]. They subdivided colonies based on morphology: round,
mass, grape-like, and stellate. They concluded that stellate morphology is correlated with
aggressiveness and invasiveness. These stellate colonies predominately lacked the
expression of E-cadherin (cell adhesion molecule) expression, which is considered to be a
tumour suppressor in solid tumours. Another group performed a similar study in a panel of
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24 cell lines to find the best genes for predicting stellate morphology in 3D cultures [115].
They found genes that genes known to regulate cancer hallmarks (such as proliferation) in
different cell lines are highly expressed in stellate colonies. Another predicted gene for
stellate morphology is paralemmin-2 (PALM2), which has been found to be responsible for
filipodia and spine formation during dendritic branching. In PCa, some cell lines consist of
heterogeneous morphology with stellate and round colonies [102]. Gene profiling for the
stellate colonies revealed genes enriched in cell adhesion, cell-to-cell contact,
invasion/metastasis, and extracellular matrix (ECM) turnover [102]. Genes involved in
epithelial mesenchymal transition (EMT), a critical mechanism used by metastatic cells for
migration, were highly enriched in cell lines that form stellate morphology in 3D cultures
that showed highly expressing mesenchymal markers such as vimentin, fibronectin, and Ncadherin [102].

1.10 Rationale
Metastatic cells have the capacity to alter their morphology to achieve the key steps
involved in the metastatic cascade. PCa cell lines commonly used in studies are quite
heterogenous in their morphology. As will be evident from my studies, DU145 and PC3M-LN4 PCa (cells with high metastatic potential when compared with other classical PCa
cell lines) formed metastatic colonies that exhibited relatively higher stellate morphology
versus round morphology in the CAM model. As this is not a robust readout (heterogeneity
in cell and colony morphology), I proposed using benign prostatic hyperplasia (BPH) cells
to assess which kinases alter the morphology of these benign cells. In 3D cultures, BPH
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form homogenous colonies with round morphology. Therefore, any alteration in BPH
morphology can be reliably measured and may identify kinases which may make PCa cells
aggressive.

1.11 Hypothesis
I hypothesized that several kinases that are altered by the CRISPR-Cas9 system will
produce a phenotype shift in the morphology of benign prostatic hyperplasia cells when
grown in 3D culture, revealing candidate kinases as putative regulators for prostate cancer
invasion.

1.12 Research Objectives
To test my hypothesis, I have devised a set of four objectives. These are divided into in
vitro (3D cultures) and in vivo (CAM) segments of my studies:
In vivo studies: 1) To identify a metastatic prostate cancer cell line that will form stellate
colonies in vivo; 2) To generate a DU145 subline that is capable of forming 100% colonies
with a stellate morphology in vivo
In vitro studies: 1) To optimize plating conditions of Cas9 overexpressing BPH clones as
grown in Matrigel; 2) To perform a CRISPR-Cas9 kinase screen to identify sgRNAs that
induce a stellate morphology in vitro
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Chapter 2

2

Materials and Methods

2.1 Cell Culture (2D)
DU145 cells are metastatic PCa cells derived from the brain [103]. These cells were
maintained in DMEM. PC3-M-LN4 was initially derived from the bone [104] and was
maintained in RPMI media. BPH cells, an inflammatory cell line extracted from a 68-yrold patient undergoing transurethral resection of the prostate for urinary obstruction [105],
were maintained in RPMI. All media were supplemented with 10% FBS, 100 IU/mL
Penicillin, 100 µg/mL streptomycin and incubated at 37°C and 5% CO2. DU145 and PC3M-LN4 cell lines were lentivirally infected with a ZsGreen vector to intravitally visualize
the cells in the CAM model.

2.2 Cell Culture (3D)
Cells were embedded between two layers of Matrigel. For the bottom layer, 175 µL of
100% Matrigel was added into one well of the 24 well/plate and incubated at 37°C (5%
CO2) for 30 minutes to be polymerized. Cells were next counted and seeded at 1×104
cells/mL density (~1500 cells/ well) on top of the Matrigel layer. Cells were left for 30
minutes to allow attachment. For the upper layer, 150 µL of 20% Matrigel/culture medium
was added to cover the cells. Fresh medium was added every two days. After 7-10 days,
colonies were counted using the inverted microscope and/or used for cytochemistry.
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2.3 CAM Injection
DU145-zsGreen and PC3-M-LN4-zsGreen cells were counted using the hemocytometer
chamber and injected at 1×106 cells/mL density (~1×105 cells/CAM). The cell suspension
was kept on ice prior to and during the injection period to maintain cell viability.
Afterwards, the cells were injected under a dissecting microscope via a microinjector which
consists of four parts: a syringe, a needle, tubing, and micropipette-pulled needle. During
and after the injection, the CAM model was immediately visualized under the fluorescent
microscope to confirm cell injection. After 7 days, micrometastases were either counted for
colony formation efficiency or extracted for passaging and injection.

2.4 Extracting micrometastases out of the CAM
After 7 days post injection into the CAM and under the fluorescent microscope, colonies
of interest were picked up by fine forceps and cut out by fine scissors. Then, the extracted
colonies were individually dissected from any associated extra tissue by a sterile scalpel.
Each colony was sub-cultured in one well of the 24 well/plate and fed with the preferred
medium supplemented with (10X) hyaluronidase, (10X) collagenase, and a potent
antibiotic (100X) normocin.
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2.5 Extracting Hits out of Matrigel
We extracted hit colonies that exhibited a phenotype shift in 24 well/plate using a 1 mL
syringe, tubing, and a fine borosilicate needle after assembling them. We then used a
microscope with a screen to follow the fine needle, point it to a colony of interest, and then
aspirate it with the syringe. The extracted hit was then subcultured in one well of a 24 well
plate. Extracted colonies were individually left to expand and proliferate for 3‒4 weeks
before DNA extraction and sgRNA identification.

2.6 Bacterial transformation
Plasmid DNA was transformed as stated in the manufacturer’s protocol of the DH5α
Competent Cells (ThermoFisher Cat. No. 18265017). Five µL (1 ng) of plasmid DNA was
added to 1 µL of the competent cells in a centrifuge tube and gently mixed. The mixture
was incubated on ice for 20 minutes. In order for the bacteria to absorb the plasmid, the
mixture was heat shocked at 42°C for 45 seconds and returned to ice for 2 minutes. Two
hundred µL of LB medium without antibiotic was added to the mixture and incubated at
37°C for 40 minutes at 225 rpm. Fifty µL of the bacterial cells were then streaked on LB
agar plate with an appropriate antibiotic and incubated at 37°C for overnight. Another plate
was used for growing only the competent cells as a negative control for the experiment.
One day later, an individual colony from the agar plate was inoculated into 5 mL of LB
medium supplemented with an appropriate antibiotic (Ampicillin) and incubated, grown at
37°C for overnight at 225 rpm. Plasmid DNA was purified from the bacteria for
downstream experiments.
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2.7 DNA purification
2.7.1 Bacterial Plasmid Purification
DNA purification was performed as per the manufacturer’s protocol (Geneaid Cat. No.
PD100). In brief, bacterial culture was spun down at 10,000 x g for 10 minutes, and the
supernatant was discarded, leaving behind the bacterial pellet. A number of different
buffers were subsequently added to the bacterial pellet as follows: 200 µL of suspension
buffer, 200 µL of lysate buffer, and 300 µL of neutralization buffer. Then, the mixture was
centrifuged at 16,000 x g for 3 minutes. The supernatant was transferred to the binding
membrane column and centrifuged for 30 seconds. The flow-through was discarded. The
binding membrane was washed with 700 µL of washing buffer and centrifuged for 3
minutes, and the flow-through was discarded. The column was placed in a new centrifuge
tube, and 30 µL of the elution buffer was added and centrifuged for 2 minutes to get the
eluted DNA.

2.7.2 DNA Extraction from Mammalian Cells
Total DNA was purified from the transduced cells using Puregene Core Kit A (Qiagen)
following the manufacturer’s instructions. Three hundred µL of cell lysis solution was
added to the cell pellet and vigorously agitated at high speed for 10 seconds. Ten µL of
protein precipitation solution was added and vigorously agitated at high speed for 20
seconds. Subsequent centrifugation for the mixture was performed for 1 minute at 16,000
x g. The supernatant was gently poured out into 300 µL of isopropanol in a centrifuge tube.
The mixture solution was manually and gently inverted 50 times. Subsequent centrifugation
was performed for 1 minute at 16,000 x g, and the supernatant was discarded leaving behind
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a white DNA pellet. The DNA pellet was washed with 300 µL of 70% ethanol and spun
down for 1 minute at 16,000 x g. The supernatant was discarded, and the DNA pellet was
left to air dry for 5 minutes. One hundred µL DNA hydration solution was added and
incubated at 65°C for 1 hour to dissolve the DNA. DNA was quantified using the
NanoDrop™ 1000 Spectrophotometer (Thermo Fisher Scientific). DNA samples were then
amplified using standard PCR for sequencing.

2.8 Conventional PCR
PCR was conducted based on the manufacturer’s instructions (NEB Cat. No. M0270L). In
a centrifuge tube, 1 µL of 10 µM forward/reverse primers were mixed with 1 µg of DNA
template, 12.5 µL of Taq 2X Master Mix, and Nuclease-free water to a total of 25 µL. The
PCR reaction was processed in 96-well Bio-Rad MyCycler Thermal Cycler for 30 cycles
(95°C for 15-30 seconds, 45-68°C for 15-30 seconds, and 68°C for 1 minute per kilo base).
After incubation, 4 µL of DNA loading dye was added to the reaction tube and loaded
subsequently into agarose gel wells. The PCR product was extracted by DNA Gel
Extraction Kit (NEB, Cat. No. T1020L), and the PCR product was used to generate
genomic products for cloning or sequencing. A list of primers used is presented in Table
1.
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Table 1: List of PCR primers
Gene

Sequence

Cas9

F: CAAGTTCATCAAGCCCATCC
R: ATGTCCAGTTCCTGGTCCAC

Tks4

F: GCGTCGAGACCCAACTTTCT
R: TCTTTAGACCATGGCAACCCC

pLX-sgRNA

F: AGCGCTAGCTAATGCCAACTT
R: GCCGGCTCGAGTGTACAAAA

b-Actin

F: AGAGCTACGAGCTGCCTGAC
R: AGCACTGTGTTGGCGTACAG

2.9 Gel electrophoresis
One % of the agarose powder was melted in Tris/Borate/EDTA (TBE) buffer (0.5 g/50 mL)
in an Erlenmeyer flask using the microwave. One µL of the ethidium bromide (EtBr) was
subsequently added into the agarose liquid. At moderate temperature, agarose was poured
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out into the gel tank (Bio-Rad Cat.1704467), and a comb was placed at the (-) electrode for
creating the wells for loading the samples. After 15 minutes, the samples were run at 120
V for an hour. The gel was then visualized and captured using Gel Doc™ XR+ Gel
Documentation System (BioRad).

2.10 DNA gel extraction
This technique was accomplished following the manufacturer’s protocol (NEB Cat.
T1020L). DNA bands were visualized on top of a UV light box. Bands of interests were
excised and trimmed from any gel excesses using a new and clean blade. Each band was
put into an individual centrifuge tube, and four volumes of the dissolving gel buffer was
added to the gel inside the tube (400 µL/100 mg) and incubated at 50°C for 10 minutes.
The melted gel slice was allowed to go through the binding membrane of the column and
centrifuged for 30 seconds. The binding membrane was then washed with 700 µL of the
washing buffer and centrifuged for 3 minutes. The elution buffer was preheated at 50°C,
and 6 µL was added to increase the DNA yield.

2.11 Immunofluorescence (2D)
Eight mm glass coverslips were placed in 24 well/plate prior to cell culture. The cells were
grown on top of these coverslips overnight. Cells were then fixed using 10% formalin for
15 minutes. Cells were washed three times and then blocked and permeabilized by a
mixture of 0.01% Triton™ X-100 and 1% BSA. Primary antibody was diluted in 1% BSA
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at appropriate dilution (1:1000) and incubated at 4°C overnight. The primary antibody
solution was aspirated, and the coverslips were then washed three times with PBS. The
secondary antibody was diluted in 1% BSA at appropriate dilution (1:2000) and incubated
at room temperature for an hour. Prolong mounting medium with DAPI (Invitrogen Cat.
P36931), was dropped on top of the slides, and the coverslips were placed upside down on
the slide. The cells were then visualized under the confocal microscope. A list of antibodies
used is given in Table 2.

2.12 Immunofluorescence (3D)
Small dishes with glass at the bottom (MatTek Cat. No. P35G-0-10-C) were used to
enhance imaging resolution for this assay. Prior to staining, cells were immersed in
Matrigel (Corning® Cat. No. CACB354234) as previously demonstrated in Section (2.2).
Cells were fixed by adding a mixture of 20% acetone and 80% methanol and incubated for
20 minutes at 4°C. After aspirating the fixative, cells were gently washed 3X with PBS to
protect the Matrigel, and 3% BSA was subsequently used for blocking for 1 hour. Primary
antibody was diluted in 3% BSA at low dilution (1:200) and incubated for one hour.
Secondary antibody, diluted as above, was added for one hour. Prolong mounting medium
with DAPI was gently dropped on top of cell matrix and a square cover slip was placed on
top of it. The colonies were then visualized under the confocal microscope.
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Table 2: List of Fluorescent Dyes and Antibodies
Fluorescent Materials

Source (Cat. Number)

Anti-CRISPR-Cas9 antibody

Abcam (ab191468)

Anti-human Tks4 Antibody

Milliporesigma (09-267)

Anti-β-Actin Antibody

abm (G043)

Alexa Fluor™ 488 Phalloidin

ThermoFisher (A22287)

ProLong™ Gold Antifade Mountant

ThermoFisher (P36931)

with DAPI

Dextran

ThermoFisher (D1868)

DyLight 649 labeled Lens Culinaris

Vector Laboratories (DL-1048)

Agglutinin (LCA) (Lectin)
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2.13 qRT-PCR
Total RNA was isolated from cells using RNAeasy Mini kit (Qiagen). In brief, the cells
were lysed with 300 µL of cell lysis buffer and subsequently agitated at high speed and
centrifuged for 3 minutes at maximum speed. The supernatant was gently aspirated and
mixed with 300 µL of 70% ethanol. The total volume was then transferred onto RNeasy
Mini spin column in a 2-mL collection tube and centrifuged for 15 s at ≥8000 x g. The
flow-through was discarded. The spin column was washed with 700 µL of washing buffer
and centrifuged for 3 minutes. The column was then placed in a new centrifuge tube, and
30 µL of RNase-free water was added and centrifuged for 2 minutes. RNA was quantified
using the NanoDrop™ 1000 Spectrophotometer (Thermo Fisher Scientific). One µg of
RNA was reverse transcribed to cDNA using qScript™ cDNA Synthesis Kit
(QuantaBiosciences). One hundred ng of cDNA was amplified with primers listed in Table
1. Actin was used as the housekeeping gene. Samples were run on QuantStudio 5 qPCR
(Thermofischer Scientific US). For each reaction, 1 µL of 10 µM forward/reverse primers,
1 µL of 100 ng DNA template, 5 µL SYBR Green qPCR Mastermix, and Nuclease-free
water was added to yield a 10 µL reaction mixture. The PCR conditions were 40 cycles of
denaturation at 95°C for 15s and annealing at 60°C for 1 min followed by a melt curve
stage.
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2.14 Western blotting
Lysate mixture consisting of RIPA buffer (Sigma-Aldrich Cat. No. R0278-50ML) and
protease inhibitor cocktail was added to the cells, and cells were lysed using a cell scraper.
Proteins from different cell lines were then quantified by the Bradford assay. Ten-times
Reducing agent and 4X sodium dodecyl sulfate (SDS) were added based on protein
quantity. Samples were then boiled for 10 minutes for protein denaturation. Samples were
run on a gel at 120 V for an hour. Polyvinylidene difluoride (PVDF) membrane was
immersed in methanol to be activated and placed within sponges, filter papers as well as
the gel and transferred at 30 V for 2 hours. PVDF membrane was then blocked with 1-3%
skim milk in TBS-T and incubated in 1 hour at RT. Primary antibody was diluted at
appropriate concentration (1:1000) in 1-3% skim milk/TBS-T and added to the membrane
and incubated overnight at 4°C. The membrane was then washed three times with TBS-T
for 15 minutes, and secondary antibody was subsequently added after being diluted in 13% skim milk/TBS-T (1:5000) and incubated in an hour at RT. One mL of Luminata
Crescendo Western HRP substrate (Millipore_Sigma Cat. WBLUR0100) was added on top
of the PVDF membrane, and protein bands were developed and visualized using the
ChemiDoc XRS System.

34

2.15 Confocal microscopy
Intravital and confocal images were captured using a Nikon Fast A1R Resonance Confocal
Microscope as described previously [106]. To capture circulating cancer cells and/or
established colonies in the CAM, Lectin (binds to glycocalyx on the endothelial cells) and
Dextran dyes were injected into the CAM to illuminate the vessel lumen and the luminal
surface of endothelial cells. The model was then placed in a special chamber with a special
lid with a centered hole for placing coverslip to maintain position.

2.16 Lentiviral production and transduction
For preparing the virus, we used the human embryonic kidney (HEK)-293T cell line. Two
µL of the transfection agent (X-tremeGENE) was mixed with 250 µL of an Opti-MEM
medium and incubated at RT for 5 minutes. The second mixture was packaging (2.25 µg):
envelope (0.25 µg): and the Cas9 (2.5 µg) plasmids together. The two mixtures were mixed
and incubated at RT for 20-30 minutes and then were added drop-wise to the HEK293 cells.
After 16 hours, the medium was removed and fresh medium with high serum was then
added. One day later, conditioned medium was aspirated and viruses aliquoted and stored
at -80°C for downstream experiments.
For transducing viruses into the cells, old medium was removed from the cells and 2 mL
fresh medium supplemented with 4 uL of polybrene (at a stock of 4ug/uL) was added.
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Viruses were then added drop-wise into the cells. A day later, the medium was removed
and replaced by media with an appropriate antibiotic for selecting only the transduced cells.
A list of vectors used is presented in Table 3.
Table 3: List of used Vectors
Vector Name

Source (Cat. Number)

LentiCRISPR v2 (Cas9)

Addgene (52961)

pLX-sgRNA (Kinase Library)

Addgene (50662, 51045)

psPAX2 (Packaging)

Addgene (12260)

pCMV-VSV-G (Envelop)

Addgene (8454)

2.17 Kill Curve Assay
Approximately 5000 cells/well were seeded in a 96 well/plate and incubated overnight. A
range of eight different concentrations of Puromycin (0-10 µg/µL) and Blastcidin (0-20
µg/µL) were added in triplicate. After three days, 100 µL of the AlamarBlue dye, which
produces a fluorescent signal in response to metabolic activity, was added for 2 hours. The
optical density of the plate was measured by microplate reader at 655 nm.
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2.18 MOI Determination of Kinase Library
Cells at 3×105 density were plated per well into a 6-well plate. Then, cells were infected
with different amount of virus: Untreated cells (control), 63 µL, 125 µL, 250 µL, and 500
µL. After 24 hours, the media was replaced with the selection media containing 25µg/mL
blasticidin. After selection, cells were harvested and counted.

2.19 Sequencing and sgRNA Kinase identification
DNA sequencing was performed at the London Regional Genomics Centre, Robarts
Research Institute, London, Ontario. Each sample consisted of 10 µL of 3‒5 ng PCR
product and 5 µL of 2 µM forward or reverse primers. We used SnapGene Viewer software
to analyze the sequencing results. Once the sequencing results were obtained, we matched
the sgRNA amplicon sequence of the hits with the kinase library by comparing to the file
deposited by Dr. David Sabatini and Dr. Eric Lander on the Addgene website.

2.20 Statistical Analysis
GraphPad prism software was used for all tests. A one-tailed unpaired student t-test was
used for analysis. Data are presented as mean ± standard deviation (SD). A probability
value P < 0.05 was considered statistically significant.
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3

Results

3.1 DU145 PCa cells are more effective at metastatic
formation exhibiting a higher percentage of stellate
morphology
There are many metastatic PCa lines and it is not clear which are more metastatic or
aggressive [19], [34]. Thus, we utilized two cell lines to assess the suitability for our studies.
For conducting the CRISPR screen, an aberrant colony morphology among homogenous
ones is needed for sgRNA identification. Therefore, the cell line forming more colonies
with homogenous morphology would be more favorable for the CRISPR screen. Two
metastatic PCa cell lines were evaluated in vivo for their morphology and ability to form
metastases. DU145 cells and PC-3M-LN4 cells were injected at 1×106 cells/mL (~1×105
cells/CAM) into embryonic Day 9 chicken embryos. These cells were permanently
expressing ZsGreen by viral transduction for visualization under fluorescence stereoscopy.
At 7-days post-injection, we counted the number of cancer colonies using fluorescence
stereoscopy and enumerated stellate-shaped colonies versus non-stellate colonies. In an in
vivo model, metastatic cells usually form more stellate colonies in the CAM model
compared to round colonies seven days post-injection. Thus, our readout in vivo was a
phenotype shift into round. Our results showed that DU145 PCa cell line is more effective
at metastatic colony formation and that the majority of these exhibit a stellate morphology
(Fig 3)
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Figure 3: DU145 cells exhibited higher metastatic efficiency and a higher percentage
of stellate morphology relative to PC-3M-LN4 cells
A) A bar graph showing that DU145 cells form more colonies (170.1 ± 13.5
colonies/embryo) than the PC-3M-LN4 cells (24.4 ± 4.5). Ninety percent of DU145
colonies exhibited a stellate morphology compared to only 35% for PC-3M-LN4. B)
Representative image for a DU145 stellate colony established in the CAM stroma at 7-days
post-injection. C) Representative image for a DU145 round colony established in the CAM
stroma at 7-days post-injection, Lectin and Dextran dyes were used to illuminate blood
vessels. Results as a mean +/- SD.
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3.2 Isolation of stellate colonies from the CAM model and
subculture
The cell lines used in our study did not form homogenous ‘stellate’ morphology. Therefore,
we sought to establish a cell line that is capable of forming a homogenous stellate colonies.
It has been shown that serially culturing metastatic colonies after isolation from the host
will enrich the isolated cells with more aggressive characteristics relative to the parental
cells. Thus, we isolated a total of 70 CAM-colonies from DU145 that exhibit a stellate
phenotype and passaged them in culture for a second-round of CAM injection (Fig 4).
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Figure 4: Isolation of stellate colonies from the CAM model and subculture
A) A pie chart demonstrating 40 of the isolated colonies that grew in culture. B) A simple
comparison in 2D culture between regular DU145 and an isolated colony. C)
Representative images of isolated colonies growing in culture using the bright field with
the green channel. DC#: DU145 Colony#.
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3.3 DU145 sublines increased the percentage of stellate
colonies
Only 40 out of 70 isolated colonies were able to grow in culture. Colonies failed to grow
in culture mostly due to technical errors. Other growing colonies grew in culture but divided
at a low rate or were contaminated. These were all discarded. A total of 20 colonies were
contamination-free and grew in culture. These were injected into the CAM model in order
to evaluate whether their stellate phenotype is enhanced. The number of stellate colonies
were counted at 7-days post-injection (Fig 5).

Figure 5: DU145 sublines formed higher percentage of stellate colonies compared to
the parental cells
A bar graph showing that the second round cancer cell formed relatively higher percentage
of stellate colonies (93-98%) compared to parental DU145 (83%) (shown in red) after one
round of in vivo passaging. Results as a mean +/- SD. DC#: DU145 Colony#.
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3.4 DC-1- subline formed invadopodia and expressed Tks4
All sublines, after being injected into the CAM model, produced colonies that have
relatively similar stellate morphology compared to the original cell line DU145, except DC1- subline which produced a distinctive phenotype in its stellate form.
In order to evaluate further, we plated DU145 and DC-1- in Matrigel. This assay closely
mimics the in vivo environment by allowing the cells to expand clonally in a 3D
environment surrounded by matrix. After 7 days, both cell lines form colonies with a
mixture of stellate and round morphology. Interestingly, DC-1- cells formed protrusions
mimicking invadopodia (Fig 6A-B). These protrusions were not seen in DU145 cells.
We next examined these cell lines at the molecular level. A body of evidence revealed that
Tks4 is responsible for protrusion formation, especially invadopodia [107]. Our results
showed that DC-1- robustly express Tks4 at the mRNA and protein level over the regular
DU145 (Fig 6C-D).
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Figure 6: DC-1- subline form invadopodia and express Tks4
A) Two representative images of DU145 colony in stellate state that did not form any
protrusions when plated in 3D culture model (insets show higher magnification images).
B) DC-1- forming protrusions (insets show higher magnification images). Black arrows
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indicating protrusions. C) qPCR analysis of Tks4 mRNA revealing that DC-1- expressed
Tks4. D) Immunoblotting showing high expression of Tks4 in DC-1- subline relative to the
original DU145. β-actin was used as a loading control and a housekeeping gene. *p<0.05.

3.5 A schematic diagram for the in vivo CRISPR screen
A schematic illustrating the in vivo model and hit discovery following CRISPR kinase
library screen is shown in Fig 7. This model needs to be optimized before moving to the
CRISPR screen as the screen relies on a morphology shift. When a colony has a kinase
deficit that causes a stellate colony morphology to shift into a round morphology, this
would suggest that this kinase suppresses aggressiveness and eventually metastasis. Having
a homogenous phenotype of stellate shaped colonies is required for the screen. However,
our model did not produce homogenous stellate morphology (Fig 7). DU145 cell line and
its sublines failed to produce 100% of stellate morphology in the vivo model.
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Figure 7: Schematic for the In vivo CAM model screening
Schematic for the in vivo screen. Top panel (A) is depicting what the in vivo model should
ideally show. Attaining a homogenous “stellate” morphology is critical for the CRISPR
kinase library screen. In the middle lower boxes, each colored circle represents a KO
kinase. Right lower panel (B) showing a boxed black arrow at a phenotypic shift to round
as a putative hit.
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3.6 Determining BPH cell plating efficiency in Matrigel.
Since it is challenging and time consuming to establish a cell line that is capable of forming
a homogenous “stellate” morphology, we reasoned that a cell system which may shift from
a homogenous round to a stellate colony may be more sensitive and specific. We selected
BPH cells as an alternative cell line for this purpose. BPH cells form a homogenous round
morphology after plating in Matrigel. Therefore, we selected this cell line and assessed
plating efficiency before proceeding to the screen. We plated BPH cells at 6×103, 3×103,
and 1.5×103 in 24-well plate in triplicate in Matrigel. Growing colonies were monitored
and imaged daily (Fig 8). The colonies were then manually counted at 7-days post-plating
using an inverted microscope (Fig 9A). For determining the plating efficiency, we divided
the overall number of colonies by the number of plated cells and multiplied it by a hundred
(number of colonies formed ÷ number of cells plated) ×100. Our results revealed that
1.5×103 has the highest plating efficiency relative to others (Fig 9B).
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Figure 8: Wild type BPH growing in Matrigel (3D culture) for 7 days
A timeline of normal BPH cells growing in Matrigel throughout the 7 day study. Cells
exhibited homogenous round morphology. Inset in all images depicting a higher
magnification. At day 4, some BPH colonies start to reach their full size.
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Figure 9: Plating efficiency of BPH cells in Matrigel.
Optimization for the plating efficiency for colony formation in Matrigel. A) BPH cells were
plated in Matrigel and number of colonies were enumerated at 7 days from plating. B) a
density of 1.5×103 showed the highest plating efficiency. Results as shown as a mean +/SD. **p<0.05.
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3.7 Kill Curve Assay for determining appropriate antibiotic
selection concentration
Before we transduce BPH cells with Cas9 vector or CRISPR-Kinase library, we performed
a kill curve assay to determine the effective concentration of an antibiotic to kill untransduced cells completely. Here, we used two antibiotics; puromycin and blasticidin in
order to utilize them for selection of Cas9 and CRISPR kinase library transduced BPH cells.
Our data shows that puromycin is an effective selectable marker for Cas9 at 2µg/mL and
blasticidin for kinase sgRNA-infected cells at 25µg/mL concentration (Fig 10).
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Figure 10: Kill Curve Assay for selectable markers
Top panel depicting 2µg/mL of Puromycin as the minimal concentration required to
completely kill BPH-wildtype cells. Lower panel depicting 25µg/mL of Blasticidin as the
minimal concentration required for completely killing BPH-wildtype cells.
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3.8 BPH cells expressing Cas9
BPH cells were then lentivirally transduced with LentiCRISPR-V2, a vector which
constitutively and stably expresses Cas9. This vector has been shown to have a ~10-fold
increase in functional viral titer over other vectors, particularly lentiCRISPR-V1 [108].
Constitutive Cas9 expression is critical for generating an efficient knockout [49], [109].
BPH-Cas9 expression was confirmed by Western blotting and immunofluorescence in 2D
and 3D culture (Fig 11).
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Figure 11: BPH cell lines stably expressing Cas9
A) Western blot for Cas9 expression in infected BPH cells with Cas9 vector vs BPHwildtype (WT) cells (two replicates). β-actin was used as a loading control. B)
Immunofluorescence for Cas9 expression in 2D culture (purple color represents Cas9, blue
color represents DAPI staining). C) Immunofluorescence for Cas9 expression in Matrigel

54

3D culture (purple color represents Cas9 expression, green represents actin for phalloidin
staining, and blue represents DAPI staining).

3.9 Generating BPH-Cas9 clone 122 with high induction of
Cas9
We attempted to generate a BPH-Cas9 clone with a high and homogenous expression of
Cas9. We conducted single cell expansion to generate clones with distinctive and different
expression of Cas9. We performed a serial dilution to have 10 cells in 1 mL of media in 15
mL tube. We then added 100 µL of cell suspension into all wells of a 96 well plate, and we
left each cell to proliferate for 2-3 weeks, with media changes every week. We next
subcultured the clones for immunostaining to evaluate the level of Cas9 expression. BPHCas9 clone number 122 showed the highest expression as well as a relatively homogenous
population compared to other clones (Fig 12).

55

Figure 12: BPH-Cas9 clone 122 has a higher expression of Cas9
BPH-WT was used as a negative control for Cas9. Representative images for different
BPH-Cas9 clones. Cas9 number 122 clone has a higher expression for Cas9 relative to other
clones. C-#: Clone-#.
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3.10 Putative hit for CRISPR-Kinase library
Our study so far has shown that BPH colonies grow with a round morphology (Fig 9,13A).
This represents an excellent model for the screen since false positive hits will be highly
minimized.
CRISPR kinase library has 6,012 sgRNA sequences with 8-10 sgRNAs designed for per
kinase. Each sgRNA was subcloned into pLX vector with a Blasticidin resistance gene as
a selectable marker. Library transformation was slightly different than the standard
transformation, as per Section 2.5. Four µL of the library clones were distributed into 8
vials of competent cells (vial/5 µL) and incubated in ice for 20 minutes. Then, cells were
heat-shocked by placing them in 42° C water bath for 45 seconds. The tubes were returned
to ice and kept for 2 minutes before adding 125 µL of Recovery Medium into each tube.
We then pooled all the tubes into one tube and added 50µL in each of the 20 agar plates
(150mm). The following day, we scraped all colonies with a cell scraper and pooled them
in one 50 mL conical tube. After centrifugation , we proceeded to DNA purification using
Maxiprep kit which has the capacity to yield the maximum amount of DNA.
After making the viruses, we determined the Multiplicity of Infection (MOI) of BPH-Cas9
cells. A range of different virus volumes was tested for this assay, and the 30% MOI for
BPH-Cas9 cells was 180 µL of virus (Fig 1) [each cell has a 30% chance for viral infection].
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Figure 13: Schematic for the In vitro Screen (3D culture)
Schematic cartoon for the in vitro screen. Top panel is depicting the in vitro model without
the CRISPR-Cas9 kinase library. BPH colonies are able to produce a homogenous “round”
morphology, and this homogeneity is of critical importance prior to the CRISPR screen. In
the middle lower panel, each colored circle represents a KO kinase. Right lower panel
depicting a boxed black arrow indicating phenotype-shift to a stellate morphology revealing
it as a putative hit.
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Figure 14: MOI Determination for Kinase Library
A line graph depicting MOI determination for kinase library. One hundred eighty µL of the
virus is capable of infecting nearly 30% of cells.
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BPH-Cas9 cells were infected with the CRISPR kinase library, and after selection with
Blasticidin for two days, cells were immediately plated in Matrigel in three 24 well/plates
to ensure a whole coverage of the library (3X). Cells were observed under an inverted
microscope daily throughout the experiment. Phenotype-shift into a stellate one was
observed (Fig 15).
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Figure 15: CRISPR-Kinase hits in BPH cells growing in 3D culture
Putative hits after infection of BPH-Cas9 cells with the CRISPR-Kinase library revealed a
phenotype-shift into a stellate one. Top left image: a representative colony of BPH-Cas9
growing in 3D culture. All other images depicting a CRISPR-Kinase hit. Note that some
hit colonies exhibited a significant shift in morphology (a complete disruption of the round
morphology), and others demonstrated a moderate shift (protrusion formation).
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3.11 The identification of hits
Seven days from plating the transduced cells with CRISPR-kinase library in Matrigel, we
sought to isolate putative hits shown in (Fig 15). In total, we were able to extract 30 colonies
and 6 of these isolated colonies were observed growing in culture afterwards (Fig 16). Hit
growing colonies were kept in culture for over a month to yield enough cells for DNA
extraction. Only four contamination-free colonies persisted and survived throughout the
experimental period. These colonies showed substantial variation in terms of doubling time.
Approximately 7 ×104 to 2×106 cells were lysed to get genomic DNA. Subsequently, the
sgRNA amplicon was amplified by PCR followed by agarose gel electrophoresis. Expected
band size was observed and excised. We next performed sequencing analysis for the
sgRNAs. For further validations, extracted amplicons from the gel were run again to ensure
the presence of DNA before sequencing (Fig 17).
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Figure 16: Proportion for the number of extracted “hits” from Matrigel
We isolated 30 hits from Matrigel. A) 6 colonies were observed from the day following
isolation. B) Two representative images for the isolated hits from Matrigel growing in vitro
2D culture.
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Figure 17: Hit identification
A) Cartoon depicting the isolated colonies. B) Left: line illustrating DNA and red color
indicting the sgRNA amplicon. Right side right showing a white strand in a centrifuge tube
and the red\black arrowhead indicating the genomic DNA. C) DNA bands for hits on
agarose gel at the indicated size. D) DNA bands after excision. E) Extracted bands were
then run again on agarose gel to confirm the presence of DNA.
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3.12 Glycogen synthase kinase 3 beta (GSK3ß) as a potential
regulator for prostate cancer invasion
Once we received the sequencing results, we matched the sgRNA amplicon sequence of
the hits with the kinase library (an excel file deposited by Dr. David Sabatini & Dr. Eric
Lander through Addgene website). One of the hits revealed Glycogen synthase kinase 3
beta (GSK3ß) as a putative candidate for prostate cell morphology change (Fig 18). The
sequencing results for two hits did not match the kinase library. We also did not retrieve
sequence results from 3rd potential hit as there was not enough DNA for sequencing.
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Figure 18: GSK3ß as a putative regulator for morphological change and prostate
cancer invasion
Top panel illustrating sgRNA sequence using SnapGene Viewer software, and sgRNAGSK3ß is highlighted by the yellow color. Lower panel is the pooled sequences for kinases
in an excel format. GSK3ß sequence is indicated by the red rectangle. The sequence of
sgRNA- GSK3ß is AGGAGACAAGGACGGCAGCA.
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4

Discussion

4.1 In vivo CAM Model
The aim of this study was to perform an in vivo/in vitro CRISPR screening for kinases that
may regulate prostate cancer metastasis.
For the in vivo model, we chose the chicken embryo as a screening model for candidate
kinases. This animal model is convenient, cost-effective, highly vascularized (Fig 3), and
amenable to real-time imaging. We injected metastatic PCa cell lines into the CAM model
to monitor the morphology of colonies at 7-days post-injection. These colonies were
expected to produce a homogenous “stellate” morphology [110] indicating an aggressive
cell behaviour. Obtaining homogenous colonies was important so that when an individual
kinase within these colonies is knocked out by the CRISPR-Cas9 system, a morphologyshift into a round one will take place.
DU145 vs PC-3M-LN4 cell lines
The CAM injection results for both cell lines revealed compatible results with previous
work regarding metastasis [111]. Metastasis is an inefficient process, and this has been
extensively studied. Luzzi and colleagues have shown that only 0.02% of the melanoma
B16F10 cells form metastases in the animal model [112]. The metastatic efficiency for PC3M-LN4 was found to be 0.03%, and 0.1% for DU145 in the CAM model. Surprisingly,
the results for comparing the metastatic potential between both cell lines after injection into
the CAM showed that the DU145 cells were three times more likely to be metastatic
compared to the PC-3M-LN4 cell line (Fig 4). There are three classical PCa cell lines: PC-
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3M-LN4, DU145, and LNCaP. The two former cell lines are androgen-independent, and
the later one is androgen-dependent [113]. Our group showed that these androgenindependent cells are highly metastatic compared to LNCaP [studies performed in the
laboratory by Patrick Telmer, data not shown here]. PC-3M-LN4 is a highly representative
of PCa metastatic ability [114], [115], [116] relative to DU145 [117]. Furthermore, it is a
subline of PC-3 which is a metastatic PCa cell line derived from the human bone. PC-3 was
injected and metastasized to the lymph node of the mice. This cycle has been rounded four
times [104]. This number of passages of the cell line is expected to make it more aggressive
and metastatic than DU145 cell line. Two explanations may be formulated from these
observations. First is the extravasation step at day 9 for the CAM injection. The results
from the extravasation assay, which typically starts at day 13 of the chicken embryo,
revealed that PC-3M-LN4 extravasates well when compared with day 9 injection (0.03%
vs 0.09%) [studies performed in the laboratory by Yohan Kim, data not shown here].
Injection at day 9 for the colony formation assay is of a critical importance because the
lifetime for the embryos is limited to 18-20 days [97]. Thus, injection of cells at the early
age will allow them to proliferate into a colony. Second, the DU145 cell line may have
higher metastatic potential since this line is derived from the brain and would have
penetrated the blood-brain barrier (BBB) [118], [119]. Metastatic cancer cells tend to
metastasize to the brain at a very late stage compared with other distant sites [120]. Another
study showed that DU145 can proliferate in the bone environment after intratibial
inoculation into the mouse [121], whereas the LNCaP cell line did not survive or proliferate
[122], [123]. These studies suggest that the DU145 cell line may be similar to PC-3, which
is a bone-derived cell line.
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Colonies Passaging
Multiple lines of evidence have shown that a subline may have distinctive differences from
the parental population in melanoma [124], breast cancer [125], [126], and prostate cancer
[104]. Serial passages of PCa cells could potentiate the cells' metastatic potential by
facilitating genetic alterations and independence from androgen hormones [104].
Therefore, we sought to do the same and isolate a subline with more invasive properties
(Fig 5), which eventually will form a homogenous stellate morphology compared to the
parental cell line. Overall, most of the generated sublines showed a high degree of
invasiveness by forming a greater percentage of stellate colonies relative to the parental
DU145 cells after injection into the CAM model (Fig 6).
Interestingly, DC-1- subline showed distinctive properties over the original DU145 cell
line. DC-1- formed protrusions after plating in 3D culture Matrigel and significantly
expressed Tyrosine kinase substrate with four SH3 domains-4 (Tks4) at mRNA as well as
at the protein level (Fig 7). Tks4 is an adapter protein that is well known for protrusion
formation, podosome formation and cell adhesion [107]. The status of a related protein,
Tks5, in DU145 is unknown. We evaluated the mRNA levels of Tks5 in both cell lines, and
neither showed any positivity. This might due to the environment for the cells during
harvesting prior RNA extraction. Tks5 is a very well known mediator for invadopodia
formation, a critical protrusive structure for facilitating cell extravasation [127]. We also
speculate that these are not lamellipodia, because this lamellipodia protrusion appears only
in 2D culture [128], [129]. Invadopodia and lamellipodia are hard to distinguish [127],
[130]. Podosomes are distinctive from invadopodia since the former are found in normal
cells such as macrophages and endothelial cells, and invadopodia are found in neoplastic
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cells [131]. However, they share strong similarities that they are both included under the
umbrella term invadosome [132]. Other markers can be used to identify protrusion
formation, in particular invadopodia, including cortactin and the neural Wiskott-Aldrich
Syndrome protein (N-WASP).
The use of PCa cells for the proposed CRISPR kinase screen was found to be limited. Both
parental as well as the DC-1- subline did not produce a pure population of colonies with
stellate morphology (Fig 8). Thus, it is challenging and time-consuming to establish a cell
line that is capable of producing a homogenous set of stellate colonies if this morphology
is still the readout of the screen. Thus, we adapted the normal BPH cell line for these
studies.

4.3 In vitro
The BPH cell line has the capability, along with other cell lines [133], to produce a
homogenous round colony morphology in Matrigel [134], [135], [102]. BPH cells were
implanted in Matrigel to confirm the homogeneity of the round colonies. My results show
that BPH colonies exhibited a round morphology (Fig 9). I then plated different BPH cell
densities to determine the plating efficiency for colony formation. The results showed that
1.5×103 produced a higher plating efficiency of colonies relative to densities. Although 36×103 cells formed more colonies, its plating efficiency was low (Fig 10). A probable
reason for this drastic decrease of the number plated cells is the apoptotic response for these
cells due to loss of cell-cell contact [136]. Determining the plating efficiency is of critical
important to have an enrichment of the whole kinase library. For example, if 3×103 or 6×103
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cells with low plating efficiency were plated, 64-82% of the library clones will be lost after
subjecting to CRISPR kinase library (Fig 10).
Lentiviral transduction can generate a stable expression of a recombinant protein and is a
widely used platform to introduce genetic material [137]. Since each BPH-Cas9 cell will
be individually infected with a sgRNA kinase clone, cells will need to exhibit a high and
homogenous expression of Cas9 for effective knockout. Several lines of evidence
suggested that attaining a homogenous expression of a protein is not possible [138], [139].
However, we generated BPH-Cas9 clone number 122, which met our expectations (Fig
13). The BPH-Cas9-122 cells were subjected to the CRISPR kinase library and treated with
Blasticidin antibiotic for selecting only infected cells. The MOI was determined with
unmodified BPH cells, so cells were infected at low MOI (0.3) to ensure at least one cell
will take up only one viral construct [88]. Another approach we used to minimize off targets
events and MOI was that we maximized the number cells relative to the library clones prior
transduction [140].
After plating the transduced cells in Matrigel, some colonies exhibit a morphology shift
[141], and these colonies were isolated for sgRNA identification. Some exhibited a
significant shift as a result of complete disruption of the round morphology, and others
exhibited a moderate shift by forming protrusions. This protrusion formation may be due
to invadopodia or podosome formation. Podosomes are exclusively formed in nonmalignant cells, and these include BPH cells. We also noticed that during incubation and
throughout the experiment, a considerable number of cells appeared dormant in contrast to
the BPH-WT cells plated in Matrigel. This observation was not surprising since the kinase
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family occupies the majority of oncogenes in cancer [62]. In addition, the plating efficiency
was greatly reduced with kinase KO (10.6%) compared to typical BPH cells (45%).
Hit colonies were picked using a microneedle under the microscope and transferred to fresh
media. Thirty colonies with potential hits were isolated and sub-cultured. The following
day, only 6-8 colonies were observed to be growing in culture (Fig 16). These clones
exhibited a substantial variation in terms of doubling time. Beaver and his group divided
this kind of cell behavior for such clones into three groups: holoclones, showing extensive
proliferation and self-renewal; meroclones, having limited proliferative capacity and
cannot self-renew, and lastly paraclones, which are incapable of additional proliferation
[142]. Eventually, only four isolated colonies persisted in culture. These cells were lysed
for DNA isolation, and sgRNA amplicons were amplified. The sequencing results revealed
that GSK3ß is potentially involved in mediating morphological changes and possibly PCa
metastasis (Fig 18).
Glycogen synthase kinase 3 beta (GSK3ß) is a serine/threonine kinase. It was initially
extracted from rat skeletal muscle as a kinase that phosphorylates and inactivates glycogen
synthase (GS) to inhibit glycogen synthesis. GS is considered to be the last enzyme
involved in glycogen biosynthesis [143]. GSK3 is involved in many pathological disorders
[144]. Its role in cancer is not fully established. Some studies show that GSK3ß has a tumor
suppressor role by controlling Wnt signaling and ß-catenin degradation [145]. In addition,
the absence of GSK3ß expression is correlated with advanced PCa [146]. Other studies
revealed that GSK3ß is involved in oncogenesis [147]. GSK3ß has a role in cell cycle
regulation through cyclin-dependent kinase (CDK) modulation [145]. Multiple GSK3ß
inhibitors have been identified for neurological and diabetes disorders [148]. Type 1
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diabetics lack the insulin hormone that is responsible for converting glucose to glycogen;
suppression of glycogen synthase kinase 3 (GSK3) promotes conversion of glucose into
glycogen [166]. Other GSK3ß inhibitors were found to be effective for other types of cancer
such as ovarian [149], leukemia [150], pancreatic [151], [152] and colon cancer [153]. A
study revealed that the GSK3ß protein is an oncogene in PCa, and its suppression leads to
decrease in the tumor burden [154]. Lithium chloride (LiCl), TDZD-8, and L803-mts are
GSK3 inhibitors. LiCl and TDZD-8 suppressed the growth of human prostate tumor
xenograft in mice. In another transgenic adenocarcinoma mouse prostate (TRAMP) model,
TDZD-8 and L803-mts administration reduced the presence of prostate tumour lesions.
Several limitations for GSK3 inhibitor use have been found. Since GSK3 regulates Wnt
signaling and ß-catenin, some types of cancer have mutations in these proteins. GSK3 is
also known to phosphorylate oncogenic transcription factors such as c-MYC and c-JUN
[155]. GSK3 inhibition in this case would be anticipated to dephosphorylate and activate
these transcription factors. In our in vitro screen, we consider GSK3ß as a tumor suppressor
as it changed the normal/benign morphology of a colony into one generally associated with
an aggressive phenotype [156]. If true, this identification may lead to a novel approach for
cancer therapy [157]. This, of course, requires additional studies to confirm the knocking
out of GSK3ß at the protein level in addition to mRNA level. In addition, studies are needed
to directly modulate GSK3ß and determine whether morphological changes are indeed
present. Conducting cell migration assay/invasion assay to assess its role are also needed.
In our studies, we utilized BPH and PCa to identify kinases which may regulate metastasis.
To appreciate the results of this study, it is important to discuss the properties of BPH and
PCa cells. The former is recognized to develop from the transitional and central zones (TZ
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and CZ, respectively) of the prostate gland. The latter develops from the peripheral zone
(PZ). A link between the two disorders has been found based on epidemiological studies,
clinical trials, in vitro experiments, and autopsy samples [158]. BPH is representative of
an inflammatory disorder, and PCa along with other types of cancer are known to be
preceded by chronic inflammation. In the majority of prostate cancer biopsy samples,
inflammation is detected either within the tumour or in close proximity to it. A study was
conducted on 180 males with suspected PCa who were diagnosed at baseline and after five
years of follow-up. After five years, 20% of patients showed inflammatory signs on their
biopsies; however, in 6% of the patients, the biopsies did not show any sign of baseline
inflammation. Measurements of C-reactive protein (CRP) levels, which is a circulating
inflammatory marker, have been correlated with PCa progression. Genetic analyses have
shown that mutations in the RNASEL (encodes 2-5A-dependent ribonuclease) and MSR1
(encodes macrophage scavenger receptor types 1 and II) genes, both of which are involved
in the response to infection, are correlated with increased risk of prostate cancer.
Proliferative inflammatory atrophy, which is known to precede PCa and intraepithelial
neoplasia, has also been shown to arise from areas in the prostate in which cells are actively
regenerated following tissue injury caused by various pathological processes such as
infection. Since inflammation play an important role in cancer, treating PCa patients with
anti-inflammatory agents could minimize the risk of PCa. This association between the two
disorders has significant clinical implications because it reveals the question of whether
BPH can predict the risk of developing PCa.
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4.3 Limitations
We faced a number of limitations in our CRISPR screen for kinases. First, we attempted to
use the in vivo CAM model for the screen. However, a lack of homogenous colony
formation by PCa cells prevented progression of studies. Measuring changes in the number
of metastatic colonies as a readout may be performed in other animal models. Second is the
inability to have a homogenous expression for Cas9 cells, which may lead to in efficient
kinase KO. Since there were 8-10 sgRNAs for each kinase member, we hoped this number
of clones can compensate for the possibility of low Cas9 expression. Third, isolating
colonies from the Matrigel medium is inherently difficult. Our successful isolation rate was
only 20% and we lost the majority of the hits during the isolation process. This end-point
experiment can be improved with more advanced techniques that allow for precisely
extracting a colony with a low potential for contamination. Another way to improve colony
viability after isolation is to design a special medium, as in the case with stem cells
passaging in Matrigel by using E8 medium [159].

4.4 Future Directions
There is need of further studies for screening the kinase library and validating it. This
research provides fundamental strategies and methodologies for developing CRISPR-Cas9
KO kinase library using BPH cells in vitro. The kinases that regulate the hallmarks of
cancer can be screened for different cancer cells, in particular, metastatic prostate cancer
cell lines such as DU145, PC-3, and LNCaP. For the in vitro model using an invasion assay,
cells that invade well should be sequenced and selected as targets for the identification of
potential invasion suppressors. However, migration assay is particularly difficult because
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the whole library will be mixed, and hits and non-hits will be indistinguishable. Identifying
kinases whose loss exerted proliferative or metastatic behaviour will be a key for the
development of treatments for PCa. Moreover, kinases that confer resistance to current PCa
therapy can be identified. By treating the KO kinase cells with these drugs, genes that confer
resistance to these drugs will be negatively selected. In addition, an in vivo screen can be
performed to uncover kinases involved in intravasation, extravasation, and metastatic
formation step whether by administering KO kinase cells intravenously, subcutaneously,
or orthotopically in the mouse model. Overall, CRISPR-Cas9 genomic editing system is a
novel approach to delineate the function of genes and their involvement in different
pathological disorders, including cancer.
GSK3 contributes to many cellular functions. There is a need to test its function in PCa
using the three classical PCa cell lines: PC-3, DU145, and LNCaP. Evaluating its
expression at the protein and mRNA levels would be useful for determining if these cells
have an altered function of this gene product. Knocking this gene out could be used to
evaluate its contribution to colony formation or morphological changes in 3D culture.
Forming colonies in soft agar has been correlated with tumorigenesis [180]. Performing
cell migration and cell invasion assays would help to determine whether silencing this gene
would attenuate or potentiate tumorigenesis in these cell lines.
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